Emergent Biosolutions is resuming production of Johnson & Johnson's COVID-19 vaccine at its Baltimore facility. Production was halted in April after components of the AstraZeneca vaccine, which was also being produced at the plant, were found to have contaminated a batch of Johnson & Johnson vaccines. The FDA also found a number of sanitation problems at the plant. The plant can produce up to 120 million doses per month. Deliveries of the vaccine are scheduled to begin in the fall.
Emergent Biosolutions is resuming production of Johnson & Johnson's COVID-19 vaccine at its Baltimore facility. Production was halted in April after components of the AstraZeneca vaccine, which was also being produced at the plant, were found to have contaminated a batch of Johnson & Johnson vaccines. The FDA also found a number of sanitation problems at the plant. The plant can produce up to 120 million doses per month. Deliveries of the vaccine are scheduled to begin in the fall. 
reuters.com
English (US) 